No abstract

Background: Small cell lung cancer (SCLC) is an aggressive malignancy with a short median survival time. Because of the rapid growth rate there may be an advantage to emergently beginning chemotherapy as soon as SCLC diagnosis is made. Methods:All SCLC patients evaluated at Cooper University Hospital from January 2011 to September 2014 were reviewed. Multiple clinical factors were analyzed including timing between diagnosis and start of chemotherapy.Results: A total of 75 patients were analyzed. On univariate analysis there was a survival detriment to early initiation of chemotherapy. With multivariate analysis the difference in survival disappeared. With logistic regression, the only variable that was related to overall survival was stage (extensive versus limited). We did not find any subset that benefited from early initiation of chemotherapy.Conclusions: Mortality and cumulative survival time were not improved by early initiation of chemotherapy for any patient subset. Only stage at diagnosis was predictive for mortality and cumulative survival. Our data appears to show that urgency in starting chemotherapy has little bearing on survival in patients diagnosed with SCLC. The data suggest that there is no detriment to a non-urgent start time for chemotherapy. status (including potentially compromising the integrity of informed consent), strain hospital systems with the costs of inpatient chemotherapy and delayed discharge, and interfere with proper disease staging.

Background: Haemodialysis patients usually have symptoms of either mentally or physically experienced before or during or after their procedure. This study evaluates the frequency of experienced symptoms, negatively effect of functioning, regardless of acuity, and well-being can be measured in terms of bio physiological parameters as BP, Pulse rate, Respiratory rate and SpO2. Methods:In this study convenience sampling technique was used to correlate the symptom experiences and bio-physiological parameters of 200 hemodialysis patients using one to one interview with the set of framed symptoms.Results: During AV Fistula cannulation, the major symptoms seen were fear, anxiety, irritation, anger and sadness. The main physical symptom experiences by HD patients was pain, drowsiness, fatigue, headache, palpitations, numbness, nausea/vomiting and, breathlessness. There was increase in pulse rate, blood pressure, heart rate, and decrease in the respiratory rate in majority of patients. The most relevant and highly significant were pulse rate due to fear and irritation and increase in hear rate and respiration due to pain and breathlessness. Conclusion:This study suggests that nursing and physicians' team should consider reducing problems of haemodialysis patients by training and counselling. More is warranted to improve the quality of life which can be resulted from exercise counselling and encouragement in hemodialysis patients.

The MYC oncogene has been implicated in the pathogenesis of many types of human cancer. The Felsher laboratory uses a conditional Tet-off MYC mouse model to study the formation of tumors in multiple tissue types, such as lymphoma, and has demonstrated that MYC-induced tumorigenesis is reversible. We have found that many cancers are “oncogene addicted” to MYC. Our laboratory has shown that an adaptive T cell-mediated immune response is essential for sustained tumor regression upon MYC inactivation (Rakhra et al, Cancer Cell, 2010). Now, we have found evidence suggesting that upon MYC inactivation in tumors, B cells are activated and are critical to tumor regression. MYC inactivation in a tumor was associated with the induction of an antibody-mediated response against tumor cells. This humoral response could mediate the killing of tumor cells in an Antibody-Dependent Cellular Cytotoxicity (ADCC) assay. Our work suggests that MYC inactivation results in a B cell-mediated immune response and that ADCC may contribute to tumor regression. Citation Format: Stephanie C. Casey, Rachel K. Do, Dean W. Felsher. The role of the immune system in sustained tumor regression following oncogene inactivation. [abstract]. In: Proceedings of the AACR Special Conference on Myc: From Biology to Therapy; Jan 7-10, 2015; La Jolla, CA. Philadelphia (PA): AACR; Mol Cancer Res 2015;13(10 Suppl):Abstract nr B02.